Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03690388 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) -Targeted Therapy

StatusActive, Not Recruiting
PhasePhase 3
SponsorExelixis
Started
View on ClinicalTrials.gov ↗

Record History

  1. Completion date: Dec 2024 to Jul 31, 2026v38
  2. Completion date: Dec 2023 to Dec 2024v37
  3. Re-verified, no change to tracked fieldsv36
  4. Results first posted: May 18, 2023v35
  5. Completion date: Dec 2022 to Dec 2023 Site details revised at 2 of 164 sitesv34 Show 1 more changeShow less
    • Site details revised at 2 of 164 sites
Show 32 earlier versionsHide 32 earlier versions
  1. Enrollment target: 258 to 187 Collaborators expanded, about 1 wordv33 Show 1 more changeShow less
    • Collaborators expanded, about 1 word

    See this version in full on ClinicalTrials.gov ↗

  2. Study sites: 163 to 164v32
  3. Re-verified, no change to tracked fieldsv31
  4. Trial status: Recruiting to Active, Not Recruiting Enrollment target: estimated 300 to confirmed 258 · Study sites: 159 to 163 · Primary completion date changed from estimate of Jul 2020 to Aug 19, 2020 · 2 morev30 Show 5 more changesShow less
    • Enrollment target: estimated 300 to confirmed 258
    • Study sites: 159 to 163
    • Primary completion date changed from estimate of Jul 2020 to Aug 19, 2020
    • Eligibility criteria expanded, about 26 words
    • Study title expanded, about 6 words

    See this version in full on ClinicalTrials.gov ↗

  5. Study sites: 154 to 159v29
  6. Study sites: 150 to 154v28
  7. Study sites: 143 to 150v27
  8. Study sites: 133 to 143v26
  9. Study sites: 128 to 133v25
  10. Study sites: 123 to 128v24
  11. Study sites: 116 to 123v23
  12. Study sites: 111 to 116v22
  13. Study sites: 98 to 111v21
  14. Study sites: 95 to 98v20
  15. Study sites: 94 to 95v19
  16. Study sites: 86 to 94v18
  17. Study sites: 81 to 86v17
  18. Study sites: 55 to 81v16
  19. Study sites: 35 to 55v15
  20. Study sites: 31 to 35v14
  21. Study sites: 28 to 31v13
  22. Study sites: 21 to 28v12
  23. Study sites: 17 to 21v11
  24. Study sites: 11 to 17v10
  25. Study sites: 10 to 11v9
  26. Site details revised at 1 of 10 sitesv8
  27. Study sites: 9 to 10v7
  28. Study sites: 7 to 9v6
  29. Study sites: 5 to 7v5
  30. Study sites: 2 to 5v4
  31. Study sites: 1 to 2 Start date changed from estimate of Oct 2018 to Oct 5, 2018v3 Show 1 more changeShow less
    • Start date changed from estimate of Oct 2018 to Oct 5, 2018
  32. Trial status: Not Yet Recruiting to Recruiting Study sites: 0 to 1v2 Show 1 more changeShow less
    • Study sites: 0 to 1
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Exelixis
25 trials monitored
See 2 trials at risk
Thyroid Cancer
387 trials monitored
See 23 trials at risk
The objective of this study is to evaluate the effect of cabozantinib compared with placebo on progression free survival (PFS) and objective response rate (ORR) in subjects with Radioiodine-Refractory Differentiated Thyroid Cancer (DTC) who have progressed after prior vascular endothelial growth factor receptor (VEGFR)-Targeted therapy.
Trial Details
NCT Number NCT03690388
Lead Sponsor Exelixis
Collaborators: Ipsen
Conditions Differentiated Thyroid Cancer
Enrollment 187 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov